Rafael Pharmaceuticals (Formerly known as Cornerstone Pharmaceuticals, Inc.)
1 Duncan Drive
59 articles with Rafael Pharmaceuticals (Formerly known as Cornerstone Pharmaceuticals, Inc.)
Rafael Pharmaceuticals Joins the Pancreatic Cancer Action Network’s Scientific & Medical Affairs Industry Membership
Rafael Pharmaceuticals Inc. (“Rafael” or the “Company”), a leader in the growing field of cancer metabolism-based therapeutics, announced today that it has joined the Scientific & Medical Affairs Industry Membership of the Pancreatic Cancer Action Network (“PanCAN”), a worldwide leader in the fight against pancreatic cancer.
11/4/2019Even clinical trial announcements don’t slow down for Halloween. It was a typically busy week. Here’s a look.
Rafael Pharmaceuticals Appoints Chief Medical Officer, José Octávio Costa Filho, M.D.Dr. Costa Filho joins alongside Timothy Pardee, M.D., Ph.D, who will remain as Co-Chief Medical Officer
Rafael Pharmaceuticals Inc., a leader in the growing field of cancer metabolism-based therapeutics, announced that José Octávio Costa Filho, M.D., will join the company as Chief Medical Officer.
Rafael Pharmaceuticals Reaches Milestone of 25 Active Sites for Pivotal Phase 3 Trial (ARMADA 2000) of CPI-613® (devimistat) in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML)
Rafael Pharmaceuticals, Inc., a leader in the growing field of cancer metabolism-based therapeutics, today announced the milestone activation of 25 sites for its pivotal Phase 3 clinical trial (ARMADA 2000) of CPI-613® (devimistat) in patients with relapsed or refractory acute myeloid leukemia (AML).
10/28/2019Although the clinical trial news last week was dominated by the stunning reversal of Biogen and Eisai’s clinical trials of aducanumab for Alzheimer’s disease, there was plenty of other trial news. Here’s a look.
Rafael Pharmaceuticals Announces Expansion into South Korea of Pivotal Phase 3 Trial of CPI-613® (devimistat) in Patients with Metastatic Pancreatic Cancer
Rafael Pharmaceuticals, Inc., a leader in the growing field of cancer metabolism-based therapeutics, announced that the Phase 3 clinical trial of CPI-613® for patients with metastatic pancreatic cancer is now active in four sites in South Korea.
Rafael Pharmaceuticals Enters into Collaboration with the National Institutes of Health (NIH) to Test CPI-613® (devimistat) in Cytokine Independent (Acute) HTLV-1 Associated Adult T-cell Leukemia/Lymphoma
Rafael will provide the compound for the study.
10/14/2019It was a busy week for clinical trial announcements. Here’s a look.
9/23/2019Last week was an unusually busy week for clinical trial news, with numerous companies presenting results at conferences. Here’s a look at the top stories.
7/22/2019Here's a look at the top clinical trial news from last week, with updates from Neon, GSK, Biohaven, and more.
Rafael Pharma will utilize the investment to further advance the clinical development of devimistat (CPI-613®)
Rafael Pharmaceuticals Receives FDA Orphan Drug Designation of CPI-613 for the Treatment of Peripheral T-Cell Lymphoma (PTCL)
Rafael Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to CPI-613.
Rafael Pharmaceuticals Announces Activation of Second Clinical Trial Site for the Phase I Study of CPI-613
Newark, NJ, Aug. 13, 2018 (GLOBE NEWSWIRE) -- Rafael Pharmaceuticals, Inc., a leader in the growing field of cancer metabolism-based therapeutics, today announced the activation of a second clinical trial site for the phase I study of CPI-613 in combination with bendamustine in patients with relapsed or refractory T-Cell Lymphoma at the Abramson Cancer Center of the University of Pennsylvania. The primary objective of this study will be to determine the Maximum Tolerated Dose (MTD) of CPI-61
Rafael Pharmaceuticals Receives FDA Orphan Drug Designation for Treatment of Burkitt Lymphoma, and Initiates a Phase II Clinical Trial of CPI-613 for Patients with Relapsed or Refractory Burkitt Lymphoma/Leukemia
Rafael Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to CPI-613
Rafael Pharmaceuticals, in Collaboration with Atlantic Health System, Announces Initiation of a Phase I Study of CPI-613 in Combination with Gemcitabine and Nab-Paclitaxel for Patients with Locally Advanced or Metastatic Pancreatic Cancer
The drug is designed to disrupt the altered energy-production pathways in cancer cells by targeting their mitochondrial metabolism.
Rafael Pharma (Formerly known as Cornerstone Pharma) To Present Late Breaking Data At The 2017 European Society For Medical Oncology (ESMO) Annual Meeting
The Lancet Oncology Publishes Phase I Data Demonstrating The Safety, Tolerability, And Preliminary Efficacy Of Cornerstone Pharmaceuticals, Inc.’ CPI-613 In Combination With Modified FOLFIRINOX In Patients With Metastatic Pancreatic Cancer
FDA Provides Cornerstone Pharmaceuticals, Inc. Approval To Initiate Pivotal Study For CPI-613, Its Metabolism-Directed Anticancer Compound
Cornerstone Pharmaceuticals, Inc. Announces The Addition Of World-Renowned Experts To Scientific And Medical Advisory Boards